Oritavancin is a topic covered in the Washington Manual of Medical Therapeutics.

To view the entire topic, please or purchase a subscription.

The Washington Manual of Medical Therapeutics helps you diagnose and treat hundreds of medical conditions. Consult clinical recommendations from a resource that has been trusted on the wards for 50+ years. Explore these free sample topics:

Washington Manual

-- The first section of this topic is shown below --

General Principles

Oritavancin (1200 mg IV administered once to complete therapy) is a long-acting lipoglycopeptide (terminal half-life, 245 hours) that inhibits cell wall biosynthesis through multiple mechanisms. Oritavancin has activity against many gram-positive aerobic bacteria, including staphylococci (including MRSA) and streptococci, as well as some enterococci (including some strains resistant to vancomycin).

-- To view the remaining sections of this topic, please or purchase a subscription --